Bethesda, MD – 11 miles from District of Columbia

INTERCEPTED:

Classified Federal Government List Triggers 4,000%+ Spike In Forgotten "Sleeper Stocks"

Dear S&A Subscriber,

Have you ever heard of a San Diego-based company called Illumina (ILMN)?

Few people have. Even fewer know why this "sleeper stock" has soared 4,046% since 2003.

There were no special earnings announcements... no unusual deals inked... and no takeover bids...

The company hasn't been profiled once in The Wall Street Journal or The New York Times...

Yet Illumina shareholders have been able to turn every $10,000 invested into a whopping $416,800.

On a single stock. 

The same thing happened with Cerus (CERS), a company that works to improve the safety of donated blood.

Again... nothing remarkable or unusual happened to this company. But in 2004, it shot up 656%...

That turns every $10,000 stake into $75,600... in just 18 months.

So what's going on here?

Why are these "sleeper stocks" no one's heard of posting gains of 273%... 523%... even 4,046%... in as little as six months?

The answer lies in a classified Federal Government list – part of which recently became declassified. I have a copy in my hands...

Let me give you the full story...

Three times a year, the Federal Gov't
compiles a 1-page list of tiny U.S. stocks

My name is George Rayburn. I'm the Publisher of Stansberry & Associates Investment Research.

Recently, one of our senior researchers intercepted a very valuable document:

A 1-page list of tiny U.S. stocks, compiled by an obscure Federal agency in Bethesda, Maryland.

Typically, this document lists 10 to 15 companies. They're known to some as "sleeper stocks" – because most of them haven't gone anywhere for months, sometimes years.

But every time the Government adds them to the list – something incredible happens...

** Genvec (GNVC), a tiny pharmaceutical company that researches and produces vaccines, made the list in August 2006. Not long after, it spiked 389%...

** Omrix (OMRI), a firm that creates treatments for patients in the event of a smallpox outbreak, appeared on a 2005 list. It popped 273% shortly thereafter...

** And Aastrom (ASTM), a Michigan-based company that researches ways to treat heart disease, made it onto the list in August of 2004. It shot up 523%...

On Aastrom alone, you could have turned a $10,000 stake into $62,300... or a $20,000 stake into $124,600...

Just by following the list.

Imagine knowing – months in advance – the details of a handful of Gov't-vetted stocks that are poised to soar.

Better still, our analyst says this little-known anomaly is NOT a one-time thing.

That's because the Federal Government mandates that new lists must be issued at least 3 times a year.

Quite simply, that means you can receive a new list every few months – telling you exactly which "sleeper stocks" to buy for maximum gain – long before most people even hear of them...

Of course, no one can predict with 100% certainty what a given stock will do. But we think we've found a remarkable predictor that comes as close as possible in this business. 

Let me explain...

It all starts with a Priority Score. . .

When our researcher handed me a copy of the most recent list, I jotted down the details for my records. Take a look...

At a glance, this list probably doesn't mean much to you.

But if you know what to look for, it could put tens of thousands of dollars in your pocket in the next 12 months.

It all starts when the Federal agency assigns each stock on the list what they call a "Priority Score."

It's a complex procedure that's almost impossible for outsiders to interpret. They even use a reverse 100 – 150 scale, whereby 100 is the highest score.

According to one federal official, the Priority Score is "the most important factor for... success."

Put simply: The better the Priority Score... the higher the stock will likely soar in the next 12 months.

Take the tiny Maryland-based company Novavax (NVAX), for example.

In 2005, this "sleeper stock" received a Priority Score of 110...

In just 7 months, it spiked 1,022%...

That's the type of gain that turns every $5,000 invested into $56,100. Or $10,000 into $112,200.

It happens again and again when the Government assigns a tiny stock a Priority Score...

On Genaera alone, you could have turned a $5,000 stake into $93,400.

All 3 "sleeper stocks" were on the list... all were assigned a high Priority Score... and all shot up hundreds of percent in as little as 6 months. 

What's amazing is that you could've known about these stocks before they spiked... and before the public caught on... just by having access to the list.

But let me make something clear.

Not all publicly-listed stocks make it onto the list...

Only one specific group of stocks is ever considered by the Government for inclusion.

But the fact is, every time the Government adds a tiny stock to the list... and assigns it a Priority Score... something very important appears to happen.

And as I'll explain – it can make you a lot of money, very quickly...

Predict huge stock moves,
months in advance

I first found out about this secret list from Rob Fannon, a medical stock analyst we hired about 2 years ago.

Rob is by far our most conservative researcher. He doesn't get excited very often – and if there's one thing he avoids, it's a "hot investment tip."

Instead, what Rob has discovered is – without question – the greatest secret we've ever seen in the medical industry.

Three times a year, an obscure Federal agency compiles a list of tiny medical stocks – assigns each one a Priority Score – and the stocks have been found to rise by hundreds, sometimes thousands of percent, in less than 12 months.

Rob has only officially been on our research team for about 2 years, but he's actually been our ace in the hole for many of the best medical recommendations we've made, for nearly 5 years.

It's not surprising if you look at his background...

His passion for science first developed at East Carolina University as an Undergraduate Research Fellow – one of 12 nationwide fellowships awarded through the American Physiological Society.

Rob has an MBA and Masters in Public Health from Johns Hopkins University – ranked second only to Harvard Medical School by U.S. News & World Report. He also served on the executive board of the Hopkins Biotech Network, a student group focused on the biotechnology industry.

He was a researcher in the prestigious Comprehensive Prostate Cancer Research Program at Cedars-Sinai – alongside legendary physicians who have been profiled by CNN and USA Today.

Rob has interviewed key scientists behind some of the biggest breakthroughs in recent medical history... met with over 50 medical company executives... and is on first-name terms with folks at the American Society of Hematology, the American Society of Clinical Oncology, and the Drug Information Association.

He even set up a subsidiary biotech office in Hyderabad, India, for his U.S.-based employer.

But it was during Rob's tenure at BioServe – a small firm based in Beltsville, Maryland – that he worked on a series of genetic research projects in collaboration with the National Institute of Health...

. . . And that's where he first learned
about this secret Federal list . . .

You see, Rob first became aware of the list while working with the National Institute of Health.

Of course, I can't tell you the details of what he worked on. As you can imagine, the field of medical research is extremely competitive... so that information is confidential.

But what I can tell you is that when Rob left his old job, he was able to continue accessing this secret list – 100% legally – thanks to his "inside knowledge" of the NIH. 

Once he explained it to me, he admitted that it's already led to some of his best-performing stock picks:

	These were all "sleeper stocks"...
	They all received a high Priority Score...
	And all of them spiked within 6 months...

So what exactly are Priority Scores... and why do they appear to cause huge moves in tiny medical stocks?

More importantly, how can you get a copy of these lists?

Why a small group of Nobel Prize-winning scientists
meet in Maryland every month

The task of deciding which "sleeper stocks" make it onto the list – and assigning each one a Priority Score – is entrusted to the country's top medical professionals...

I'm talking about doctors, Nobel Prize-winning scientists, and academics from Ivy League schools like Harvard and Yale – who together make up what's known as the Scientific Review Group.

Contracted by the Federal Government solely to evaluate these tiny companies, the Scientific Review Group gets together three times a year in Bethesda, Maryland at the National Institute of Health, known simply as the NIH.

The NIH is probably the most respected medical institution in America, but few people realize that three times a year, this government agency quietly compiles a list of "sleeper stocks" that can make savvy investors extraordinary gains, 100% legally, with very little risk.

That's because the entire process of compiling the list of "sleeper stocks" is shrouded in secrecy...

Prior to the meeting, each scientist is sent a password-protected CD, which details only those companies to be considered for inclusion on the list.

The meetings are closed to the public. Reviewers – whose names are withheld by the NIH – are required to give each company a Priority Score by anonymous vote.

They're not allowed to divulge any information that is discussed... And once the meeting is over, all documentation is destroyed.

"Everything associated with the peer review meetings is confidential," says an NIH spokesman.

But there's a good reason for all the secrecy...

Many of the research applications the NIH receives contain proprietary information – technologies, products or devices that the companies don't want competitors to know about.

So confidentiality is vital.

In short, applications that are deemed to have the highest scientific merit are discussed at the review meetings, put on the list, and assigned a Priority Score.

And here's the important part:

The higher the Priority Score, the more likely the company is to receive NIH funding – which can immediately send the stock soaring.

What does all this mean for you as an investor?

Gains of 260%. . . 580%. . . even 1,189%. . .
in just 6 months

Quite simply, as long as you have access to the list I've been telling you about, it could open the door to a fortune in the medical sector... all thanks to the U.S. Government.

You see, when a medical research company receives funding from the NIH, there are four assumptions you can make:

But most important of all is what can happen to the stock price.

Take Medarex (MEDX), for example...

For the first half of 2004, this "sleeper stock" did nothing but fall. The company appeared to have no future... and nobody was paying much attention to it.

Over the next two years, however, their research team received three grants from the NIH. Take a look...

In just 3 years, the stock soared 260%.

Other "sleeper stocks" have performed just as well after receiving NIH funding:

I could go on and on. In fact, from the thousands of institutions that apply for funding each year, we looked at 71 examples where the company was assigned a high Priority Score and was awarded funding... And every one of those 71 companies went up...

That's 71 stocks examined.

And 71 winners.

Mind you, you can only make quick, triple-digit gains on smaller, more speculative companies. It's almost impossible to double your money on blue chips like Merck and Pfizer. They're simply too big...

That's why Rob only focuses on small-cap companies on the list, which have the potential for the biggest moves.

In fact, once Rob showed me the full details of how this works, he also mentioned several tiny stocks received a Priority Score most recently...

Including the single pick he believes could make you the most money, in the shortest amount of time, beginning right now.

Let me explain...

Which  tiny stock just received one of the
highest Priority Scores?

Rob has identified a small "sleeper stock" on the list that could be the best-performing stock of the next few years...

It's a small Nasdaq-listed company that has developed a highly-advanced vaccine technology, which is slated to revolutionize the use of vaccines.

In fact, the company is expected to essentially control all next-generation vaccine production. That fact alone makes it one of the most important companies we've ever recommended.

Their patented technology is so significant that pharmaceutical giants like Merck, Pfizer, and GlaxoSmithKline are lining up to use it. Several licensing agreements have already been signed.

And in October 2007, the company signed a very lucrative collaboration deal with a subsidiary of AstraZeneca, who will pay for all research and development costs... and fork over nearly $40 million in milestone payments, not including future royalties.

Plus... in December 2007, the company was awarded two 3-year contracts with the United Nations Children's Fund (UNICEF) and the Pan American Health Organization (PAHO). Together, the contracts are worth $230 million.

We believe total vaccine sales will reach $400 million by 2009. 

The scientific community is abuzz with news of these exciting technological advances. In fact, the company's researchers are actively partnered with academics from Harvard and the Walter Reed Army Institute of Research.

So it's not surprising that the company recently caught the attention of the NIH...

For six weeks, scientists and academics involved in vaccine research rigorously reviewed the company's technology... qualifications... and all its current research plans...

At the end of their investigation, the company was given one of the highest possible scores - and was immediately added to the NIH's list of companies to receive funding.

So, how high will this stock rise in the next 6 months?

Of course, I can't give you an exact number on what the gains will be, but this much is certain: Anytime a company receives a high Priority Score and funding from the NIH... the gains can be simply unbelievable...

Rob has examined the science behind this company's new technology from all angles. And he's spent weeks going through the financials.

We even conducted a conference call with the company's CFO and CEO.

He's just completed a full Report on this stock. It's called: Secrets from the NIH: The #1 "Sleeper Stock" to Buy Today.

Inside, you'll find:

But before we give you access to it, there's something you should know.

Please keep this confidential

I've been in the business for 7 years, and even now – after everything I've seen – nothing compares to the feeling of watching a tiny stock take off, turning a small stake into enough cash to buy a house... a car... or even to quit work and retire.

It's how I felt when we recommended JDS Uniphase, for example – which gained 592%... Texas Instruments (301% gains)... and Cree (271% gains)... Seabridge (700%+ gains), among many others.

Huge winners like these don't come every day, of course, but when they do we always try to recommend the pick to only a very small group of our most serious readers, who know the value of information like this.

That's why we're reserving Rob's report exclusively for our Phase 1 Investor group.

Phase 1 subscribers are the elite. They make up less than 1/10th of 1% of our total subscriber file... and demand nothing less than the highest quality analysis and recommendations.
 
While we could sell information like this to professional investors for $50,000 or more, we offer entry into Phase 1 for only a fraction of that price.

Still, it's not cheap.

That's because the only realistic way I know of to ensure this information stays confidential is to keep the price of Phase 1 Investor high. That way, I can be fairly sure that only those who are serious about this opportunity will be getting in.

So how exactly does Phase 1 Investor work? Let me explain...

Why Phase 1 Investor
May Not Be Right for You

Rob Fannon is the head analyst of Phase 1 Investor.

His mission is simple: To take the guesswork out of investing in medical stocks by learning as much "inside" information as possible.

Take Esperion, for example – a little-known California firm that works to treat heart disease.

Back in 2004, most people had no idea this company was on the verge of a major breakthrough in the field of blood circulation.

But Rob did. He worked down the hall at Cedars-Sinai Medical Center from the company's top clinical researcher, Dr. P.K. Shah.

They had lunch a few times. Rob knew the company was a strong buy. And those who followed him saw 53% GAINS OVERNIGHT when the company was bought by Pfizer (PFE).
 
Then there's a company called Sirna (RNAI)...

From his own work in genetics, Rob knew about a radical new treatment called RNAi, which treats several major disorders.

An interview with Harvard professor Judy Lieberman, Ph.D., M.D. confirmed that the science behind the treatment was sound.

And when the company made it onto the NIH list in late 2005, we alerted readers – and those who got in on our original recommendation made 203% gains in less than a year.

As you can imagine, the type of experience Rob has and the in-depth analysis he does, comes at a price.

We spend an outrageous amount of money producing this kind of research. Rob travels to meet in person with almost every company he recommends. He's been to Boston, San Francisco, San Diego, Mexico, Washington D.C., Minneapolis, New York City, Seattle, Vancouver and Atlanta in the past year alone.
 
Sometimes these research trips don't work out.

For instance, Rob found a tiny biotech company called Renovis (RNVS) who had just developed a new drug for stroke victims.

From a medical standpoint, Rob found the drug – and the company behind it – compelling... so he immediately paid a visit to his friend and colleague, the head of Johns Hopkins University Stroke Research.

Right away – his Hopkins contact said: "No way. You're flipping a coin on this."

Rob scrapped the idea. Three months later, Renovis TANKED 75% when the Phase III trial failed. Rob avoided this bomb as a result of good, hard diligence.

Biotech – unlike most other sectors – is very hard to analyze.

That's why the profit potential is so big and why so few people can do it.

You have to look beyond just the financials. You need to understand the science too. In fact, if you don't understand both, there's little chance for success.

Which is why we agreed to hire a research analyst named Dr. George Huang to work at Rob's side – solely for the purpose of locating biotech breakthroughs.

George holds a Ph.D. from Johns Hopkins School of Medicine where he worked under a 2003 Nobel Laureate in Chemistry... speaks three languages... and is published in the four best journals of his field.

He graduated high school 3 years early. By age 19, he was already working to secure private seed capital for a Vancouver-based firm called Helios Bioinformatics Inc.

George is a pro at getting under-the-radar information from top universities... labs... and venture capital firms for new technologies in the health sector.

His unique abilities complement Rob's experience perfectly... and together, they deliver unparalleled stock analysis.

So, if you like the idea of taking a very small portion of your portfolio to invest in early-stage companies that have the potential to make a fortune, Phase 1 Investor may be a perfect fit for you.

The tiny stock Rob outlines in his report, Secrets from the NIH: The #1 "Sleeper Stock" to Buy Today, is easily among the most exciting recommendations we've ever made in Phase 1.

He believes that if the firm's research proves as good as the NIH expects, the share price could more than double (even triple) in a short amount of time.

But bear in mind: This is a very small biotech stock we're talking about. There are risks. And if you're uncomfortable with risk... this is not the right kind of opportunity for you.

So how can you be sure this style of investing is for you?

A special offer. . .

The fact is, you're simply not going to find another research service that offers the kind of "behind-the-scenes" advantage Phase 1 Investor does.

That's why Phase 1 Investor is our most expensive research service.

Having said that, I believe Phase 1 Investor is actually also the best bargain of anything we publish, considering the amount of time, money, and effort that goes into each recommendation. Sometimes we have as many as 3 analysts working on each recommendation.

Boutique Wall Street firms like Ned Davis Research or David Tice and Associates charge as much as $25,000 for a single report.

One full year of Phase 1 Investor is $5,000.

If that sounds like too much money, I can tell you right now: Phase 1 Investor is not for you.

No, it's not cheap. But if you had invested in some of Rob's Phase 1 recommendations – by now you could have already made your money back... FIVE TIMES OVER...

If you think Phase 1 could be right for you, I encourage you to give it a try today... because for a limited time only, we're offering a significant discount on the regular price...

Get the next 3 Phase 1
picks, free

Yes, Phase 1 Investor is our most expensive research service.

But really... if you're making $10,000, $20,000, or even $50,000 per recommendation... is paying $5,000 too much for the information?

I don't think so.

However, you won't know for yourself, unless you try it.

That's why, for a limited time, I'd like to give you the chance to save thousands of dollars on Rob's incredible research.

And of course, your trial will be completely risk-free.

We're making this offer because we hope that if you try Phase 1 Investor... see the kind of work Rob is doing... and experience the gains he's making for his subscribers... you'll renew next year.

Here's what I recommend you do:

Note: You'll only pay the discounted price of $3,600... a saving of $1,400 off the regular price. In effect, you'll be getting your first 3 months of membership absolutely free... while others pay thousands more.

Also, as a Phase 1 Investor member, you will sometimes be invited by Rob to listen in on conference calls to learn more about his monthly investment picks.

Joining us on these calls will be the industry insiders, company executives and independent researchers Rob interviews and meets with while investigating each situation.

These calls are complimentary benefits of your membership. Of course, if you can't participate, we'll provide a complete transcript for your review.

Bear in mind, we don't offer special discounts on Phase 1 Investor very often. If anything, we should charge more.

But the situation Rob has uncovered is among the few examples of a pick that can make you more money than you've probably ever made on any single investment...

So I hope that you take advantage of this opportunity now before it expires.

For more information and to get started, Subscribe Now

Sincerely,

George Rayburn
Publisher, Stansberry & Associates Investment Research
July, 2008

P.S. Remember: Your chance to save thousands of dollars on Rob's research is good for a limited time only. If you're at all considering a trial membership, now is time to get started. This offer ends shortly. After that, you'll have to pay full price.

Subscribe Now